Jasper Therapeutics Inc.
JSPR evidence brief
What we can confirm
- BioSniper Score:
- 5.1 / 10
- Market Cap:
- $20.8M
- Lead Asset:
- briquilimab (Phase 1)
What it means
What to watch
Prepared research question
What matters most for JSPR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · JSPR
Jasper Therapeutics Inc. (JSPR) is a clinical-stage biotechnology company focused on developing therapeutics for mast cell driven diseases and immune-mediated disorders, with a lead program in briquilimab for severe combined immunodeficiency (SCID) and a pipeline including assets from the recent Kira Pharmaceuticals acquisition.
Key risk: Low cash runway pre-PIPE
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 17 clinical trials for Jasper Therapeutics Inc..
Jasper Therapeutics Inc. (JSPR) is a clinical-stage biotechnology company focused on developing therapeutics for mast cell driven diseases and immune-mediated disorders, with a lead program in briquilimab for severe combined immunodeficiency (SCID) and a pipeline including assets from the recent Kira Pharmaceuticals acquisition.
- Lead product candidate briquilimab is a monoclonal antibody targeting the CD117 (KIT) receptor, with Orphan Drug, Fast Track, and Rare Pediatric Disease Designations for SCID [sec_mda · as of 2026-08-14].
- Acquired Kira Pharmaceuticals in July 2026, adding KP-104 (Phase 2/3 ready bifunctional complement inhibitor) and KP-701 (preclinical anti-CD79BxCD32B antibody) to the pipeline [sec_mda · as of 2026-08-14].
- Cash & equivalents of $7.3M as of 2026-06-30, with net income of -$2.8M and shareholders' equity of $1.4M [sec].
- Completed a PIPE financing in July 2026 raising $132M in gross proceeds from issuance of non-voting convertible preferred stock [news · published 2026-08-14].
- Expects to announce next steps for briquilimab in SCID in the first quarter of 2027, following a pre-BLA meeting with the FDA [sec_mda · as of 2026-08-14].
What works
- Briquilimab has received Orphan Drug, Fast Track, and Rare Pediatric Disease Designations in SCID, potentially qualifying for a priority review voucher [sec_mda · as of 2026-08-14].
- The Kira acquisition added a Phase 2/3 ready asset (KP-104) and a preclinical asset (KP-701), broadening the pipeline beyond mast cell indications [sec_mda · as of 2026-08-14].
- The company raised $132M in gross proceeds from a PIPE financing concurrent with the Kira acquisition, providing capital to advance programs [news · published 2026-08-14].
What to weigh
- Cash & equivalents were only $7.3M as of 2026-06-30, with a net loss of $2.8M and shareholders' equity of $1.4M, indicating a tight cash position before the July PIPE [sec].
- The company has incurred significant losses and negative cash flows from operations since inception [sec_mda · as of 2026-05-14].
- A workforce reduction of approximately 50% was implemented in July 2025 to extend cash runway, reflecting prior financial strain [sec_mda · as of 2026-03-30].
- Briquilimab's clinical development in mast cell diseases (CSU, CIndU) is still in earlier stages, with no approved products yet [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
Briquilimab has received Orphan Drug, Fast Track, and Rare Pediatric Disease Designations in SCID.
“Briquilimab has received Orphan Drug Designation, Fast Track Designation and Rare Pediatric Disease Designation in SCID”
SEC MD&A · August 14, 2026
The company completed a PIPE financing raising $132M in gross proceeds.
“Completed a concurrent PIPE financing raising $132 million in gross proceeds”
News · August 14, 2026
Jasper expects to announce next steps for briquilimab in SCID in Q1 2027.
“expect to announce next steps in the first quarter of 2027”
SEC MD&A · August 14, 2026
Catalyst timeline
- 2017-03-20 · Phase2_Start: A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of JSP191 for Hematopoietic Cell Transplantation Conditioning to Achieve Engraftment and Immune Reconstitution in Subjects With SCID — Historical start of Phase 1/2 trial for briquilimab (formerly JSP191) in SCID conditioning.
- 2023-11-29 · Phase2_Start: A Phase 1b/2a, Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Spontaneous Urticaria (CSU) — Initiation of Phase 1b/2a trial for briquilimab in CSU, a key mast cell indication.
- 2023-12-27 · Phase3_Start: Efficacy and Implementation of Ex — Phase 3 start for an unrelated trial (likely not Jasper's); included for completeness from catalyst block.
Risks & what to watch (4)›
Key risks
- Low cash runway pre-PIPE — Cash & equivalents of $7.3M as of 2026-06-30, with net loss of $2.8M, suggests limited liquidity before the July PIPE [sec].
- No approved products — All programs are clinical or preclinical; no revenue from product sales, relying on financing and partnerships [sec_mda · as of 2026-08-14].
- Workforce reduction history — A ~50% workforce reduction in July 2025 indicates prior financial distress and potential impact on operations [sec_mda · as of 2026-03-30].
- Regulatory dependency — Briquilimab's next steps depend on FDA pre-BLA meeting outcome; any delay or negative feedback could affect timeline [sec_mda · as of 2026-08-14].
What to watch
- Pre-BLA meeting with FDA for briquilimab in SCID and announcement of next steps expected in Q1 2027 [sec_mda · as of 2026-08-14].
- Update on clinical development in mast cell mediated diseases expected in the second half of 2026 [sec_mda · as of 2026-08-14].
- Progress of KP-104 Phase 2 basket trial in rare renal indications (IgAN) [sec_mda · as of 2026-08-14].
- Potential monetization of a priority review voucher if FDA issues one for briquilimab by December 31, 2028, triggering a $30M CVR payment [sec_mda · as of 2026-08-14].
Sources: Catalysts · News · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run Jasper Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Jasper Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 7.35 · 0% dilution
Lead: Phase 1
1 candidate
No upcoming catalysts tracked
2 buys · 0 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
58
Total value held
$13.8M
| Holder | Shares | Value |
|---|---|---|
| velan capital investment management lp | 2,668,395 | $2.3M |
| millennium management llc | 1,617,531 | $1.4M |
| acorn capital advisors, llc | 1,411,492 | $1.2M |
| kingdon capital management, l.l.c. | 1,352,106 | $1.2M |
| morgan stanley | 1,333,420 | $1.2M |
| vanguard capital management llc | 1,172,597 | $1.0M |
| rock springs capital management lp | 1,100,726 | $964K |
| carlyle group inc. | 1,066,189 | $934K |
| boothbay fund management, llc | 582,751 | $511K |
| lion point capital, lp | 465,000 | $407K |
Showing top 10 of 58 institutional holders of Jasper Therapeutics Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 9.8%
- Days to cover
- 4.7
- Shares short
- 2,730,146
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
JSPR short interestGovernance
Frequently asked questions
What is the AI investment thesis for Jasper Therapeutics Inc.?
Jasper Therapeutics Inc. (JSPR) is a clinical-stage biotechnology company focused on developing therapeutics for mast cell driven diseases and immune-mediated disorders, with a lead program in briquilimab for severe combined immunodeficiency (SCID) and a pipeline including assets from the recent Kira Pharmaceuticals acquisition.
What is Jasper Therapeutics Inc.'s lead drug candidate?
Jasper Therapeutics Inc.'s most advanced tracked candidate is briquilimab (Phase 1) for Chronic Inducible Urticaria; Chronic Spontaneous Urticaria; Urticaria Chronic.
Who is the CEO of Jasper Therapeutics Inc.?
Mr. Jeetinder Singh Mahal M.B.A. is the chief executive officer of Jasper Therapeutics Inc. (JSPR).
Where is Jasper Therapeutics Inc. headquartered?
Jasper Therapeutics Inc. (JSPR) is headquartered in Redwood City, CA, United States.
What therapeutic areas does Jasper Therapeutics Inc. focus on?
Jasper Therapeutics Inc. develops therapies across Oncology, Neurology, Cardiovascular, Respiratory, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.